108 related articles for article (PubMed ID: 27479572)
1. Long-Term Outcome and Recurrence of Idiopathic Choroidal Neovascularization Treated with Intravitreal Bevacizumab.
Kim JH; Chang YS; Kim JW; Kim CG; Lee DW
J Ocul Pharmacol Ther; 2016 Sep; 32(7):431-6. PubMed ID: 27479572
[TBL] [Abstract][Full Text] [Related]
2. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization.
Wu Q; Chen X; Feng K; Liu Y; Zhang C; Zhao L
BMC Ophthalmol; 2020 Mar; 20(1):115. PubMed ID: 32192468
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
Sawa M; Gomi F; Tsujikawa M; Sakaguchi H; Tano Y
Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
[TBL] [Abstract][Full Text] [Related]
7. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis with Active Choroidal Neovascularization Managed with Intravitreal Bevacizumab.
Chen SN; Chen YL; Yang BC
Ocul Immunol Inflamm; 2020; 28(1):33-38. PubMed ID: 30994378
[No Abstract] [Full Text] [Related]
9. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
Chan WM; Lai TY; Liu DT; Lam DS
Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization.
Kang HM; Koh HJ
Am J Ophthalmol; 2013 Apr; 155(4):713-9, 719.e1. PubMed ID: 23219069
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes.
Sarao V; Veritti D; Macor S; Lanzetta P
Graefes Arch Clin Exp Ophthalmol; 2016 Mar; 254(3):445-54. PubMed ID: 26084446
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
13. SIX-YEAR OUTCOMES OF INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA.
Kasahara K; Moriyama M; Morohoshi K; Yoshida T; Simada N; Nagaoka N; Yokoi T; Shinohara K; Kaneko Y; Suga M; Ohno-Matsui K
Retina; 2017 Jun; 37(6):1055-1064. PubMed ID: 27755380
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal Bevacizumab for Nonsubfoveal Choroidal Neovascularization Associated With Angioid Streaks: 3-Year Follow-up Study.
Iacono P; Battaglia Parodi M; La Spina C; Bandello F
Am J Ophthalmol; 2016 May; 165():174-8. PubMed ID: 27013066
[TBL] [Abstract][Full Text] [Related]
15. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
Kang HM; Koh HJ; Lee CS; Lee SC
Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
[TBL] [Abstract][Full Text] [Related]
16. Treatment of choroidal neovascularization using intravitreal bevacizumab.
Pedersen R; Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
[TBL] [Abstract][Full Text] [Related]
18. Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy.
Kim H; Lee K; Lee CS; Byeon SH; Lee SC
Retina; 2015 Mar; 35(3):481-6. PubMed ID: 25313710
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study.
Saviano S; Leon PE; Mangogna A; Tognetto D
Digit J Ophthalmol; 2016; 22(2):46-53. PubMed ID: 27582675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
